Finance.yahoo.com
0
All posts from Finance.yahoo.com
Finance.yahoo.com in Finance.yahoo.com,

InPlay from Briefing.com

6:57 am GNC Holdings Increases Share Repurchase Authorization by $500 million (GNC) : ...

6:57 am Mallinckrodt plc beats by $0.22, misses on revs (MNK) : Reports Q3 (Jun) adj. earnings of $2.05 per share, $0.22 better than the Capital IQ Consensus of $1.83; revenues rose 47.8% year/year to $965 mln vs the $983.89 mln consensus.

  • Net sales for the third quarter fiscal 2015 increased $361.3 million to $446.2 million, compared with $84.9 million for the prior-year quarter. The increase in net sales was primarily driven by the inclusion and performance of Acthar and INOMAX, which collectively generated net sales of $350.2 million. In addition, net sales for the three months ended June 26, 2015 increased due to OFIRMEV growth of $8.9 million, or 16.7% from the prior-year period.

6:57 am II-VI beats by $0.04, beats on revs; guides Q1 EPS below consensus, revs below consensus (IIVI) : Reports Q4 (Jun) earnings of $0.27 per share, excluding non-recurring items, $0.04 better than the Capital IQ Consensus Estimate of $0.23; revenues rose 4.7% year/year to $196.7 mln vs the $189.93 mln consensus.

  • Co issues downside guidance for Q1, sees EPS of $0.20-0.25 vs. $0.26 Capital IQ Consensus Estimate; sees Q1 revs of $180-190 mln vs. $192.55 mln Capital IQ Consensus Estimate.

6:56 am Church & Dwight announces that effective January 1, 2016, Richard A. Dierker will succeed Matthew Farrell as CFO (CHD) : ...

6:55 am GNC Holdings to offer $250 mln in aggregate principal amount of Convertible Senior Notes due 2020 in a private offering (GNC) : The Company intends to use $100 million of the net proceeds from this offering to repurchase shares of its common stock from purchasers of Notes in this offering in privately negotiated transactions concurrently with the closing of this offering, either alone or in combination with subsequent open market share repurchases under its existing share repurchase program.

6:55 am Premier to acquire CECity, Inc., for $400 million; expects the transaction to be accretive to adjusted fully distributed earnings per share by approximately 2-4 cents in fiscal 2016, and 8-10 cents in fiscal 2017 (PINC) : ....

6:52 am Entergy misses by $0.31, misses on revs; reaffirms FY15 EPS guidance (ETR) : Reports Q2 (Jun) earnings of $0.83 per share, $0.31 worse than the Capital IQ Consensus Estimate of $1.14; revenues fell 9.5% year/year to $2.71 bln vs the $3.04 bln consensus. Co reaffirms guidance for FY15, sees EPS of $5.10-5.90 vs. $5.51 Capital IQ Consensus Estimate.

6:49 am NRG Energy beats by $0.02, misses on revs; reaffirms 2015 guidance (NRG) : Reports Q2 (Jun) loss of $0.06 per share, $0.02 better than the Capital IQ Consensus Estimate of ($0.08); revenues fell 6.2% year/year to $3.4 bln vs the $3.52 bln consensus.

  • Reaffirms full year 2015 Guidance:
    • Adjusted EBITDA of $3,200-$3,400 million
    • FCF before growth investments of $1,100-$1,300 million
    • Executed $107 million of share repurchases in second quarter for a total of $186 million repurchased year-to-date with $51 million in remaining authorized capacity and $200 million in expected capacity

6:45 am Syneron Medical beats by $0.01, beats on revs (ELOS) : Reports Q2 (Jun) earnings of $0.07 per share, $0.01 better than the Capital IQ Consensus Estimate of $0.06; revenues rose 13.8% year/year to $73.5 mln vs the $70.93 mln consensus.

  • "We achieved another solid quarter in our North America Body Shaping Division, driven by the expansion of our sales team and marketing initiatives. We remain on track with our UltraShape revenue plan for the year. We are also investing in clinical trials to expand our FDA UltraShape clinical indications for additional body areas."
  • " In 2016 we also plan to launch two additional products for facial aesthetic applications based on Candela's pulsed dye laser and solid state laser technologies combined with Syneron's proprietary ELOS technology. Additional product launches planned for 2016 include significant enhancements to our body shaping portfolio."

6:44 am Chegg Correction: Beats by $0.02, beats on revs; guides Q3 rev below consensus; raises low end of FY15 digital rev guidance, raises gross margin guidance (CHGG) :

  • Reported Q2 (Jun) EPS of $0.01, $0.02 better than the Capital IQ Consensus of ($0.01); revenues rose 4.0% year/year to $67.06 mln vs the $63.94 mln consensus.
  • Co issues downside guidance for Q3, sees Q3 revs of $74-80 mln vs. $81.63 mln Capital IQ Consensus; Adjusted EBITDA loss of between $12 million and $9 million.
  • Co issues guidance for FY15, sees FY15 revs of $295-310 mln from $310-315 mln vs. $309.57 mln Capital IQ Consensus; raises low end of FY15 digital rev, to $137-145 mln from $135-145 mln. Adjusted EBITDA of breakeven to $5 mln (from break even or better); Free cash flow in the range of $15 million and $20 million; raises gross margin to 36-38% from 34-36%.
  • CHGG has pared much of its after hours losses.

6:38 am Stereotaxis reports Q2 results (STXS) :

  • Co reports Q3 EPS ($0.12), Excluding mark-to-market warrant revaluation, vs ($0.16) year ago; revs 21.3% y/y to $9.7 mln (no estimates). Gross margin was 70% of revenue, on a higher mix of system revenue, versus 75% of revenue, in the second quarter of 2014 and 72% of revenue, in the first quarter of 2015.
  • At June 30, 2015, Stereotaxis had cash and cash equivalents of $3.6 mln, compared to $4.4 mln at March 31, 2015.

6:37 am Care.com beats by $0.08, reports revs in-line; guides Q3 EPS below consensus, revs below consensus; guides FY15 EPS in-line, revs in-line (CRCM) : Reports Q2 (Jun) loss of $0.16 per share, $0.08 better than the Capital IQ Consensus Estimate of ($0.24); revenues rose 38.0% year/year to $35.6 mln vs the $35.4 mln consensus. Adjusted EBITDA was a loss of $3.7 million in the second quarter 2015, compared to an adjusted EBITDA loss of $6.6 million in the second quarter of 2014.

  • Co issues downside guidance for Q3, sees EPS of ($0.24) - ($0.27) vs. ($0.17) Capital IQ Consensus Estimate; sees Q3 revs of $36.5-39.5 mln vs. $39.52 mln Capital IQ Consensus Estimate.
  • Co issues in-line guidance for FY15, sees EPS of ($0.68) - ($0.60) vs. ($0.67) Capital IQ Consensus Estimate; sees FY15 revs of $146-153 mln (prior guidance $146-155 mln) vs. $151.74 mln Capital IQ Consensus Estimate.

6:36 am RR Donnelley & Sons beats by $0.04, reports revs in-line; guides FY15 revs below consensus (RRD) : Reports Q2 (Jun) earnings of $0.41 per share, $0.04 better than the Capital IQ Consensus Estimate of $0.37; revenues rose 22.8% year/year to $2.75 bln vs the $2.74 bln consensus.

  • Co issues downside guidance for FY15, sees FY15 revs of $11.4-11.6 bln vs. $11.66 bln Capital IQ Consensus Estimate, down from prior guidance for $11.7-11.9 bln.
  • "As we look to the back half of 2015, we will continue to aggressively manage costs, which is reflected in our improved non-GAAP adjusted EBITDA margin guidance for full-year 2015."

6:35 am eGain Comm. reports downside prelim sales guidance (EGAN) :

  • Co sees Q4 (Jun) revs of $16.5 -17.0 mln vs. $21.66 mln Capital IQ Consensus Estimate and gross bookings $21.0 -21.5 mln. Fourth quarter new cloud bookings is expected to be 57% of total new bookings up from 25% last quarter.
  • "Although our fourth quarter revenue came in lower than prior guidance, we are pleased with our greater than 25% year-over-year growth in bookings. I am particularly encouraged with our cloud bookings that came in stronger than expected, including four on-premise customers migrating to the eGain Cloud. New cloud bookings in the quarter accounted for 57% of total new bookings, up from 25% of new bookings in the prior quarter. Several license deals we expected to close slipped out of the quarter; some have since closed."

6:35 am Regeneron Pharms beats by $0.11, beats on revs; raises EYLEA US net product sales guidance (REGN) : Reports Q2 (Jun) earnings of $2.89 per share, $0.11 better than the Capital IQ Consensus of $2.78; revenues rose 50.0% year/year to $999 mln vs the $887.59 mln consensus.

  • Collaboration revenues in the second quarter of 2015 increased primarily due to higher reimbursement of the Company's research and development expenses under its antibody collaboration with Sanofi and an increase in the Company's net profit from commercialization of EYLEA outside the United States.
  • Net sales of EYLEA in the United States increased 58% to $655 million from $415 million in the second quarter of 2014.
    • Overall distributor inventory levels remained within the Company's one- to two-week targeted range.
  • Co raises EYLEA US net product sales to +45-50% from +30-35%, lowers R&D and SG&A...

More